National Institutes of Health Consensus Development Conference Statement: Hydroxyurea Treatment for Sickle Cell Disease

Brawley, Otis W.; Cornelius, Llewellyn J.; Edwards, Louisa; Gamble, Vanessa Northington; Green, Bettye L.; Inturrisi, Charles E.; James, Andra H.; Laraque, Danielle; Mendez, Magda D.; Montoya, Carolyn; Pollock, Bradley H; Robinson, Lawrence R.; Scholnik, Aaron P.; Schori, Melissa

doi:10.7326/0003-4819-148-12-200806170-00220

Cited by 251 publications

(234 citation statements)

References 0 publications

Supporting

Mentioning

216

Contrasting

Unclassified

Order By: Relevance

“…1 However, there are barriers to implementation into clinical practice including patient and provider misconceptions about toxicity. 2,3 We now report detailed analysis of sickle cell disease-related clinical events and other adverse events (AEs) from the BABY HUG trial, which further documents the beneficial effects and lack of toxicity of hydroxyurea for very young patients with SCA.…”

Section: Introductionmentioning

confidence: 99%

Impact of hydroxyurea on clinical events in the BABY HUG trial

Thornburg

Files

Luo

et al. 2012

Blood

226

185

View full text Add to dashboard Cite

The Pediatric Hydroxyurea Phase 3 Clinical Trial (BABY HUG) was a phase 3 multicenter, randomized, double-blind, placebocontrolled clinical trial of hydroxyurea in infants (beginning at 9-18 months of age) with sickle cell anemia. An important secondary objective of this study was to compare clinical events between the hydroxyurea and placebo groups. One hundred and ninetythree subjects were randomized to hy- Continuing Medical Education onlineThis activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and the American Society of Hematology. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians. Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s) ™ . Physicians should claim only the credit commensurate with the extent of their participationin the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 70% minimum passing score and complete the evaluation at http://www.medscape.org/journal/blood; and (4) view/print certificate. For CME questions, see page 4448. Disclosures The authors, the Associate Editor Narla Mohandas, and CME questions author Laurie Barclay, freelance writer and reviewer, Medscape, LLC, declare no competing financial interests. Learning objectivesUpon completion of this activity, participants will be able to:1. Describe the effect of hydroxyurea on rates of sickle cell complications for infants with sickle cell anemia (SCA) on the basis of a phase 3, multicenter, randomized trial.2. Describe the effect of hydroxyurea on rates of hospitalizations and transfusions for infants with SCA on the basis of a phase 3, multicenter, randomized trial.3. Describe the safety of hydroxyurea for infants with SCA on the basis of a phase 3, multicenter, randomized trial.

show abstract

Section: Introductionmentioning

confidence: 99%

Impact of hydroxyurea on clinical events in the BABY HUG trial

Thornburg

Files

Luo

et al. 2012

Blood

226

185

View full text Add to dashboard Cite

show abstract

“…Studies reviewed herein provide increasing support of efficacy, effectiveness, and safety in both children and adults. In a meta-analysis of the literature through 2007, Strouse, et al studied found that in children fetal the hemoglobin levels increased from 5-10% to 15-20%; hemoglobin concentration increased modestly (approximately 1 g/L) but significantly; hospitalizations decreased by 56-87%; and the frequency of pain crisis decreased [71]. Children studied by a cooperative group remained on hydroxyurea for more than a year with only minor adverse effects, but potential complications [72].…”

Section: Hydroxyurea Therapymentioning

confidence: 99%

Non-Conventional Pain Management for Sickle Cell Disease

Al-Jafar¹

2017

Ann Hematol Oncol

View full text Add to dashboard Cite

Sickle cell disease is a congenital blood disorder affecting hemoglobin molecule. It leads to a rigid, sickle like shape red blood cell. Most people with sickle cell disease have severe painful episodes called vaso-occlusive crises. However, the frequency, severity, and duration of these crises vary tremendously. The pain is classified into two types, nociception pain which is intact peripheral or central nervous system and neuropathic pain which is initiated by dysfunction of the peripheral or central nervous system. Despite the pain being the most common complication of sickle cell disease, there is a lack of novel pain treatments. Pain killers including opioid have continued to be the main stay of therapy over the past several decades. A non-conventional treatments for pain were applied effectively to avoid the serious systemic side effects of the pharmaceutical pain killers.

show abstract

“…Sickle cell disease (SCD) is an inherited blood dyscrasia affecting 50,000 to 100,000 people in the United States [1]. Currently SCD is the genetic disease most commonly identified by the Newborn Screening Program in the US.…”

Section: Introductionmentioning

confidence: 99%